1. <div id="8sgz1"><ol id="8sgz1"></ol></div>

        <em id="8sgz1"><label id="8sgz1"></label></em>
      2. <em id="8sgz1"><label id="8sgz1"></label></em>
        <em id="8sgz1"></em>
        <div id="8sgz1"><ol id="8sgz1"><mark id="8sgz1"></mark></ol></div>

        <button id="8sgz1"></button>
        west china medical publishers
        Keyword
        • Title
        • Author
        • Keyword
        • Abstract
        Advance search
        Advance search

        Search

        find Keyword "急性呼吸衰竭" 13 results
        • Clinical Evaluation of Induced Rescue Intubation by Ketamine and Midazolam in Patients with Respiratory Failure

          Objective To evaluate the rescue intubation induced by ketamine and midazolam in patients with acute respiratory failure.Methods 81 patients with acute respiratory failure admitted between June 2010 and June 2012 were recruited in the study. They were randomly divided to a MF group to receive 0. 05 mg/kg of midazolam + 1 to 2 μg/kg of fentanyl ( n =41) , and aMK group to received 0. 05 mg/kg of midazolam + 0. 5 to 1 mg/kg of ketamine ( n =40) for rescue intubation. The APACHEⅡ score on initial24 hours after admission in ICU, length of ICU stay, and 28-day mortality were recorded. The differences in arterial blood pressure, heart rate, respiration rate, and blood oxygen saturation before intubation and 10 minutes after intubation were compared. Incidences of hypotension and other adverse events and difficult intubation were also recorded.Results The midazolamdose in the MK group was significantly less than that in the MF group ( P lt; 0. 01) . The blood pressure in both groups decreased. The systolic blood pressure dropped most significantly in the MF group ( P lt;0. 05) . The incidence of hypotension was 41. 5% in the MF group, significantly higher than that in the MK group ( 20. 0% , P lt;0. 05) . The incidence of hypotension had no correlation with midazolamdosage ( P gt;0. 05) . There was no significant difference in adverse events except for the arrhythmia between two groups. The length of ICU stay and 28-day mortality were similar in both groups ( P gt; 0. 05) . The incidence of difficult tracheal intubation was nearly 50% in both groups.Conclusions In patients with respiratory failure, rescue intubation induced by ketamine can reduce the dose of midazolam and reduce the incidence of hypotension without more complications. The optimal dose of ketamine in induced tracheal intubation requires further study.

          Release date:2016-09-13 03:54 Export PDF Favorites Scan
        • 肺部手術后急性呼吸衰竭的高危因素分析

          目的 采用Logistic回歸分析肺手術后急性呼吸衰竭的高危因素,以利于臨床應用. 方法 選取我院胸外科1991年3月~1998年12月肺手術后發生急性呼吸衰竭的59例患者(呼吸衰竭組)和未發生呼吸衰竭的279例患者(對照組)資料,相關因素數值化后,以Logistic回歸得到最主要的高危因素. 結果 危險因素包括年齡、性別、肺功能、營養狀況、吸煙指數、手術難易程度分級、合并癥(慢性阻塞性肺病年數、功能障礙器官數、哮喘和毀損肺).結論 肺外科臨床上必須針對以上因素,強調術前禁止吸煙、積極處理合并癥、控制哮喘、加強圍術期營養支持、呼吸鍛煉和減少手術創傷,以減少急性呼吸衰竭的發生.

          Release date:2016-08-30 06:32 Export PDF Favorites Scan
        • Effect of high-flow nasal cannula in immunocompromised patients with acute respiratory failure: a meta-analysis

          ObjectiveTo systematically evaluate the effect of high-flow nasal cannula in immunocompromised patients with acute respiratory failure.MethodsRandomized controlled trials (RCT) or cohort studies on the efficacy of high-flow oxygen therapy in immunocompromised patients with acute respiratory failure were reviewed by computer in PubMed, EMBASE, Cochrane Library, and China Knowledge Network, Wanfang and VIP databases. The group used HFNC and the control group used a mask or a nasal catheter to give oxygen-based conventional oxygen therapy (COT) or noninvasive ventilation (NIV). Two investigators conducted quality assessments and data extractions based on the Cochrane Collaboration Risk Assessment Manual and the Newcastle-Ottawa Scale. Meta analysis was performed using RevMan 5.3 software. The main outcome measures included tracheal intubation rate, and intensive care unit (ICU) mortality. The secondary outcomes included ICU hospitalization time.ResultsThe study included 13 articles (4 RCTs, 9 cohort studies), a total of 1133 subjects, with 583 in the HFNC group and 550 in the control group (280 in the COT and 270 in the NIV). Meta-analysis showed that HFNC was significantly different from COT in reducing tracheal intubation rate in immunocompromised patients with respiratory failure (OR=0.49, 95%CI 0.33 - 0.72, P=0.0003), but no statistical significance compared with NIV (OR=0.73, 95%CI 0.52 - 1.02, P=0.07); two-combination analysis showed that HFNC had a significant advantage in reducing tracheal intubation rate compared with COT/NIV (combined OR=0.61, 95%CI 0.47 - 0.79, P=0.0002). In terms of ICU mortality, there was a statistically significant difference between HFNC and COT (OR=0.59, 95%CI 0.35 - 1.01, P=0.05) or NIV (OR=0.63, 95%CI 0.44 - 0.91, P=0.01). The results of the two subcombinations and analysis did not change (combined OR=0.62, 95%CI 0.46 - 0.83, P=0.002). In terms of ICU hospital stay, there was no statistically significant difference between HFNC and COT (MD=?4.52, 95%CI ?9.43 - 0.39, P=0.07), but the difference was statistically significant compared with NIV (MD=?1.46, 95%CI ?2.41 - ?0.51, P =0.003); the two sub-combinations and analysis results showed significant difference (combined MD=?3.41, 95%CI ?6.16 - ?0.66, P=0.01). According to different research types, after subgroup analysis, the analysis results were not different from the combined results. Sensitivity analysis revealed that HFNC could significantly reduce the patient's ICU hospital stay compared with the control group oxygen therapy. The results of the funnel chart analysis show that there were publication offsets in the studies on tracheal intubation rate and ICU mortality included in the literature; studies on ICU hospital stays had a smaller publication offset.ConclusionsCompared with COT, HFNC can reduce the tracheal intubation rate of patients, but there is no significant difference compared with NIV; HFNC can reduce the ICU mortality of patients compared with COT/NIV. However, due to the high heterogeneity between the studies, whether HFNC can reduce ICU hospital stay remains to be further explored.

          Release date:2021-02-08 08:11 Export PDF Favorites Scan
        • 經鼻高流量氧療治療急性呼吸衰竭的隨機對照試驗

          目的評價經鼻高流量氧療治療急性呼吸衰竭的臨床效果。方法選擇重癥醫學科收治的急性呼吸衰竭患者,用隨機數字表法分為標準氧療組、經鼻高流量氧療組、無創通氣組三組,分別給予面罩吸氧、經鼻高流量氧療、無創正壓機械通氣治療。觀察患者 28 天氣管插管率、90 天全因死亡率、治療 48 h 后氧合狀況。結果共納入 116 例患者,其中經鼻高流量氧療組 40 例,標準氧療組 39 例,無創通氣組 37 例。經鼻高流量氧療組患者 28 天氣管插管率明顯低于標準氧療組(22.5% 比 51.3%,OR=0.28,95%CI 0.10~0.73)和無創通氣組(22.5% 比 48.6%,OR=0.31,95%CI 0.12~0.82);三組 90 天全因死亡率差異無統計學意義(分別為 15.0%、25.6% 和 24.3%,P=0.456)。治療 48 h 后,高流量氧療組 PaO2 較標準氧療組、無創通氣組顯著升高(P=0.006),高流量氧療組比標準氧療組提高 PaO2/FiO2 更有優勢(OR=4.02,95%CI 1.64~9.85),但高流量氧療與無創通氣 PaO2/FiO2 差異無統計學意義(P>0.05),三組患者 PaCO2、pH、呼吸頻率差異無統計學意義(P>0.05)。結論與標準氧療、無創通氣相比,經鼻高流量氧療能顯著降低急性呼吸衰竭患者 28 天氣管插管率,且有降低患者 90 天全因死亡率的趨勢。經鼻高流量氧療提高患者氧合比標準氧療更有優勢,和無創通氣效果相當。

          Release date:2020-11-24 05:41 Export PDF Favorites Scan
        • Noninvasive Ventilation for Treatment of Acute Respiratory Failure Secondary to Severe Acute Respiratory Syndrome

          Objective To investigate the effects of noninvasive ventilation for the treatment of acute respiratory failure secondary to severe acute respiratory syndrome ( SARS) . Methods 127 patients with complete information were collected from the database of SARS in Guangdong province, who were all consistent with the ALI/ARDS diagnostic criteria. The patients were divided into three groups depending on ventilation status, ie. a no-ventilation group, a noninvasive ventilation group, and a mechanical ventilation group. The outcome of ventilation treatmentwas followed up.Multi-factor regression analysis was conducted to analyze the relations of ventilation treatment with ARDS and mortality, and factors associated with success of noninvasive ventilation. Results As soon as the patients met the diagnostic criteria of ALI/ARDS, the patients in the noninvasive ventilation group were in more serious condition and had a higher proportion of ARDS compared with the no-ventilation group ( P lt;0. 01) . The patients in the mechanical ventilation group had a higher mortality rate ( P lt;0.01) . 6 and 7 patients in the no-ventilation group had noninvasive ventilation and invasive ventilation thereafter, respectively. 15 patients in the noninvasive group switched to invasive ventilation. Compared with the patients without ventilation ( n =45) , the patients receiving noninvasive ventilation ( n = 61) were in more serious condition and at higher risk of developing ARDS ( P lt;0. 01) , but the mortality was not different between them ( P gt; 0. 05) . The patients who continued to receive noninvasive ventilation ( n = 40) were in more serious condition, and at higher risk of developing ARDS compared with the patients without ventilation ( n = 45) ( P lt; 0. 01) . 15 patients in the noninvasive group who switched to invasive ventilation were older than those patients continuing noninvasive ventilation.Conclusions For SARS patients fulfilling the ALI/ARDS criteria, the patients underwent noninvasive ventilation are more severe, run a higher probability of developing ARDS from ALI. But earlier initiation of noninvasive ventilation has no impact on mortality. The patients who tolerate noninvasive ventilation can avoid intubation, especially for young patients. However, the time and indication of shifting from noninvasive ventilation to invasive ventilation should be emphasized.

          Release date:2016-08-30 11:54 Export PDF Favorites Scan
        • 納絡酮治療慢性阻塞性肺病合并急性呼吸衰竭的療效

          目的:探討納絡酮對慢性阻塞性肺病(COPD)合并急性呼吸衰竭(ARF)的臨床療效。方法: 72例COPD合并ARF患者隨機分為兩組,每組36例。治療組(A)常規給予吸氧、抗感染、祛痰、平喘,在此基礎上加用納絡酮治療。對照組(B)在常規治療基礎上加用尼克沙米、洛貝林治療。連續觀察24 h,用藥前及用藥后4 h進行動脈血氣分析,記錄臨床表現改變,并進行統計學分析。結果:A組患者血氣分析各項指標及臨床癥狀均明顯改善。兩組間PaO2,PaCO2,pH存在顯著性差異(Plt;0.05)。納絡酮組無嚴重不良反應事件。結論:〖納絡酮對慢性阻塞性肺病合并急性呼吸衰竭有良好的治療效應。

          Release date:2016-08-26 02:21 Export PDF Favorites Scan
        • The prognostic value of blood sugar level for acute respiratory failure patients undergoing mechanical ventilation

          Objectives To assess the prognostic value of blood sugar level for acute respiratory failure patients undergoing mechanical ventilation. Methods The study collected 139 acute respiratory failure patients undergoing mechanical ventilation admitted between February 2012 and October 2013. The patients were divided into a hyperglycemic group (n=123, blood sugar ≥143 mg/dl) and a non-hyperglycemic group (n=16, blood sugar <143 mg/dl). The data for basic clinical pathological characteristics and the blood sugar levels were collected, and the correlation between the blood sugar level and the prognosis was assessed using single factor analysis and logistic regression method. Results In the study, 88.49% of patients with acute respiratory failure undergoing mechanical ventilation had hyperglycemia (blood sugar ≥143 mg/dl). The proportions of patients with APACHEⅡ score ≥10, chronic obstructive pulmonary disease (COPD) or hypoxemia in the hyperglycemic group were significantly higher than those in the non-hyperglycemic group (P<0.05). APACHEⅡ ≥10, COPD and hypoxemia were significant risk factors for hyperglycemia. At the same time, the proportions of patients in the death group with hyperglycemia ≥143 mg/dl ( OR=8.354, 95%CI 1.067-65.388, P=0.018), APACHEⅡ≥10 ( OR=2.545, 95%CI 1.109-6.356, P=0.046), COPD ( OR=2.871, 95%CI 1.203-6.852, P=0.015), and hypoxemia ( OR=3.500, 95%CI 1.556-7.874, P=0.002) were significantly higher than those in the survival group. Kaplan-Meier curve analysis found that the overall survival of the hyperglycemic patients with acute respiratory failure was significantly lower than that in the non-hyperglycemic patients (P<0.001). Conclusion Blood sugar level can be used as an independent predictor for acute respiratory failure patients undergoing mechanical ventilation.

          Release date:2017-07-24 01:54 Export PDF Favorites Scan
        • Evident-Based Nursing of a Ventilation Patient with Acute Respiratory Distress Syndrome: Exploring a Reasonable Position

          Objective  To formulate an evidence-based position program for a ventilation patient with acute respiratory distress syndrome (ARDS). Methods  Based on fully assessing the patient’s conditions, the clinical problems were put forward according to PICO principles. Such database as The Cochrane Library (2005 to January 2011), DARE (March 2011), CCTR (March 2011), MEDLINE (1996 to January 2011) and CNKI (1979 to January 2011) were retrieved to collect high quality clinical evidence, and then the optimum nursing program was designed in line with patient’s conditions and relatives’ willingness. Results  Three meta-analyses, three randomized controlled trials, one systematic review and one anterior-posterior self-control study were included. The available clinical evidence displayed that: a) the prone position adopting earlier, especially for patients with bilateral lungs or left lung functional disorder, was propitious to effectively improve the oxygenation condition and reduce the incidence of ventilator induced lung injury (VILI); b) The long-term prone position could increase the risk of pressure sore; c) The prone position could prolong the survival time, but there was no enough evidence to prove that it could obviously decrease the mortality rate of ARDS. So finally a nursing plan was made in combination with literature evidence and patient’s condition: adopting the prone position after onset within 24 to 36 hours, and enhancing the skin nursing to prevent pressure sore at the same time. After 4-week comprehensive therapy and prone position ventilation, the patient got obvious alleviated in oxygenation, with SpO 2 up to 90% to 100%, stable vital signs, and no more VILI and pressure sore. And then the patient was stopped applying ventilator, and transferred to a general ward for further treatment. Conclusion  The earlier adoption of prone position ventilation for severe ARDS can improve oxygenation and reduce ventilator associated pneumonia (VAP) and VILI, but whether it can prolong survival time and reduce mortality for mild ARDS or not still has to be proved with more high quality evidence in the future.

          Release date:2016-09-07 10:58 Export PDF Favorites Scan
        • Risk factors associated with failure of noninvasive positive pressure ventilation in acute respiratory failure due to acute exacerbation of chronic obstructive pulmonary disease

          Objective To analyze the risk factors of treatment failure by noninvasive positive pressure ventilation (NPPV) in patients with acute respiratory failure (ARF) due to acute exacerbation of chronic obstructive pulmonary disease (AECOPD), and explore the best time that NPPV be replaced by invasive ventilation when NPPV failure occurs. Methods The data of patients with ARF due to AECOPD who were treated with NPPV from January 2013 to December 2015 were retrospectively collected. The patients were divided into two groups: the NPPV success group and the NPPV failure group (individuals who required endotracheal intubation or tracheotomy at any time). The Acute Physiology and Chronic Health Evaluation (APACHE) Ⅱ score was analyzed; the Glasgow Coma Scale score, respiratory rate (RR), pH value, partial pressure of oxygen (PaO2), PaO2/fraction of inspired oxygen (FiO2) ratio, and partial pressure of carbon dioxide were also analyzed at admission, after 2 hours of NPPV, and after 24 hours of NPPV. Results A total of 185 patients with ARF due to AECOPD were included. NPPV failed in 35.1% of the patients (65/185). Multivariate analysis identified the following factors to be independently associated with NPPV failure: APACHEⅡscore≥30 [odds ratio (OR)=20.603, 95% confidence interval (CI) (5.309, 80.525), P<0.001], RR at admission≥35 per minute [OR=3.723, 95%CI (1.197, 11.037), P=0.020], pH value after 2 hours of NPPV<7.25 [OR=2.517, 95%CI (0.905, 7.028), P=0.070], PaO2 after 2 hours of NPPV<60 mm Hg (1 mm Hg=0.133 kPa) [OR=3.915, 95%CI (1.374, 11.508), P=0.010], and PaO2/FiO2 after 2 hours of NPPV<200 mm Hg [OR=4.024, 95%CI (1.542, 11.004), P=0.010]. Conclusion When patients with ARF due to AECOPD have a higher severity score, have a rapid RR at admission, or fail to improve in terms of pH and oxygenation after 2 hours of NPPV, the risk of NPPV failure is higher.

          Release date:2017-11-24 10:58 Export PDF Favorites Scan
        • Safety and Efficacy of Non-invasive Positive Pressure Ventilation Treatment Combined with Fiberoptic Bronchoscopy on AECOPD Patients with Acute Respiratory Failure

          ObjectiveTo evaluate the safety and efficacy of non-invasive positive pressure ventilation (NIPPV) combined with fiberoptic bronchoscopy(FB) on acute exacerbation of chronic obstructive puhmonary disease (AECOPD) patients with acute respiratory failure. MethodsA prospective study was conducted on the AECOPD patients with respiratory failure in respiratory intensive care unit of Tangdu Hospital of Fourth Military Medicine University from February 2010 to February 2011.They were randomly divided into a case group and a control group.The case group was administrated FB and lavage after one hour of NIPPV treatment.The control group was administrated NIPPV without FB and lavage.Other treatment regimen was the same in two groups. ResultsThere were 51 subjects recruited in the study, 25 subjects in the case group and 26 subjects in the control group.All variables at baseline were matched (P > 0.05).All variables improved after one hour of NIPPV before FB, without significant difference between two groups (P > 0.05).During the period of FB, heart rate in the case group was faster than that in the control group (P < 0.05), and other variables were not significantly different between two groups (P > 0.05).Both groups received NIPPV for one hour after FB, the variables including heart rate, respiratory rate, pH, PaO2, PaCO2 were statistically significant between two groups(P < 0.05).At the time of 24 hours after FB, the variables including mean arterial pressure, heart rate, respiratory rate, pH, PaO2 and PaCO2 in the case group were nearly recovered, and differences between two groups were significant (P < 0.05).The positive rate of sputum culture was significantly higher in the case group than that in the control group[88.0%(22/25) vs.58.6%(14/26)].Success rate in the case group were obviously superior to that in control group.The cases of failure, death and refusing in the case group were lower than those in the control group.Complications in two groups had no significant difference (P > 0.05).There was not serious complication such as hear arrest, hemoptysis and apnea during the process of NIPPV combined with early FB. Conclusion It deserves to be used in clinic because of the safety, efficacy and feasible for most of AECOPD patients through NIPPV combined with early FB.

          Release date: Export PDF Favorites Scan
        2 pages Previous 1 2 Next

        Format

        Content

          1. <div id="8sgz1"><ol id="8sgz1"></ol></div>

            <em id="8sgz1"><label id="8sgz1"></label></em>
          2. <em id="8sgz1"><label id="8sgz1"></label></em>
            <em id="8sgz1"></em>
            <div id="8sgz1"><ol id="8sgz1"><mark id="8sgz1"></mark></ol></div>

            <button id="8sgz1"></button>
            欧美人与性动交α欧美精品